Department of Pathology, Vancouver General Hospital, University of British Columbia, Vancouver 1st Floor JPPN, 855 West 12th Ave, Vanouver, BC, Canada V5Z 1M9.
J Oncol. 2010;2010:740968. doi: 10.1155/2010/740968. Epub 2009 Dec 30.
Ovarian cancer is the fifth leading cause of cancer death in women in North America, and approximately two-thirds of cases of ovarian cancer are of high-grade serous type. The remaining cases are comprised of a mix of different tumor types (e.g., endometrioid, clear cell, mucinous, etc.), with no single tumor type accounting for more than 10% of ovarian cancer cases. These tumor types can be reproducibly diagnosed, and each features distinct underlying molecular events during oncogenesis, with a characteristic natural history and response rate to conventional cytotoxic chemotherapy. In this review the molecular abnormalities present in the more common non-high-grade serous subtypes of ovarian cancer will be presented. Development of targeted therapies for these tumor types will require understanding of the genetic basis of each tumor type, and may lead to subtype-specific therapy.
卵巢癌是北美女性癌症死亡的第五大主要原因，约三分之二的卵巢癌病例为高级别浆液型。其余病例由多种不同的肿瘤类型组成（例如子宫内膜样、透明细胞、黏液性等），没有任何单一肿瘤类型占卵巢癌病例的 10%以上。这些肿瘤类型可以被重复诊断，并且在致癌过程中每个都具有独特的潜在分子事件，具有独特的自然病史和对传统细胞毒性化疗的反应率。在这篇综述中，将介绍更常见的非高级别浆液型卵巢癌亚型中存在的分子异常。为这些肿瘤类型开发靶向治疗方法需要了解每种肿瘤类型的遗传基础，并可能导致针对特定亚型的治疗。
